NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- To further the fight against global lung cancer, Qure.ai, a world leader in healthcare Artificial Intelligence (AI), will unveil its AI-powered lung cancer continuum at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, from May 31 to June 4, 2024.

2024年5月29日，纽约（环球通讯社）--为了进一步对抗全球肺癌，世界医疗保健人工智能（ai）领导者Qure.ai将于2024年5月31日至6月4日在芝加哥举行的美国临床肿瘤学会（ASCO）年会上推出其ai驱动的肺癌连续体。

Featuring AI solutions to identify, measure, manage, and monitor the end-to-end care, continuum is designed to support clinicians and advance developments for lung health in the pharmaceutical and medical device industries. “Lung cancer is the leading cause of cancer-deaths worldwide, with approximately 75% of patients detected in late-stage disease.

continuum采用人工智能解决方案来识别、测量、管理和监控端到端护理，旨在支持临床医生并推动制药和医疗器械行业肺部健康的发展。“肺癌是全球癌症死亡的主要原因，大约75%的患者在晚期疾病中被发现。

Earlier detection reduces the need for therapeutic or surgical intervention and boosts survival rates, by over 90% if treatment starts at stage 1,” states Prashant Warier, CEO and Co-founder of Qure.ai. “Artificial intelligence for lung cancer powers early detection—not just as part of existing screening programs, but by finding small pulmonary nodules, often opportunistically, during general healthcare imaging procedures.

Qure.ai的首席执行官兼联合创始人Prashant Warier说：“如果治疗从第一阶段开始，早期发现可以减少治疗或手术干预的需要，并提高生存率90%以上。肺癌的人工智能不仅可以作为现有筛查计划的一部分，而且可以在一般的医疗保健成像程序中发现小的肺结节，通常是机会性的。

This enables earlier identification and referral for imaging or treatment pathways. It also helps overcome the ongoing challenges of low lung cancer screening appointment uptake rates,” Prashant Warier adds. The Qure.ai lung cancer continuum provides regulatory-cleared* individual or end-to-end detection, analysis, and monitoring tools, putting improved patient care at the heart of innovation: AI to identify missed lung nodules from chest X-rays and support in early lung cancer diagnosis;AI to measure lung nodules via CT scans and track volumetric growth as part of progression monitoring;AI to manage lung cancer cases via multi-modality reporting, collaboration and prioritization tools;AI to .

这使得能够更早地识别和转诊成像或治疗途径。这也有助于克服肺癌筛查预约率低的持续挑战，”Prashant Warier补充道。Qure.ai肺癌连续体提供了监管明确的*个人或端到端检测，分析和监测工具，将改进的患者护理置于创新的核心：ai从胸部X射线中识别遗漏的肺结节，并支持早期肺癌诊断；AI通过CT扫描测量肺结节，并作为进展监测的一部分跟踪体积增长；AI通过多模式报告，协作和优先排序工具管理肺癌病例；AI to。